Tribute Pharmaceuticals Canada Inc. (fka TBUFF)

[SAVIS]

10Q looks good to me so far..

On May 13, 2014, Tribute entered into an exclusive license and supply agreement with Faes Farma, S.A. (“Faes”), a Spanish pharmaceutical company, for the exclusive right to sell Bilastine, a product for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Canada. The exclusive license is inclusive of prescription and non-prescription rights for Bilastine, as well as adult and paediatric presentations in Canada. Sales of Bilastine are subject to receiving regulatory approval from Health Canada. Payment for the licensing rights is based on an initial fee of €250,000 ($380,691) with the remaining milestone payments based on the achievement of specific events, including the approval of Bilastine from Health Canada and net sales milestones.